The current practice for cocaine-associated chest pain in the Netherlands
- PMID: 33384944
- PMCID: PMC7770504
- DOI: 10.1016/j.toxrep.2020.12.011
The current practice for cocaine-associated chest pain in the Netherlands
Abstract
Introduction: Cocaine is considered a cardiovascular risk factor, yet it is not included in the frequently used risk stratification scores. Moreover, many guidelines provide limited advice on how to diagnose and treat cocaine-associated chest pain (CACP). This study aimed to determine the current practice for CACP patients in emergency departments and coronary care units throughout the Netherlands.
Methods: An anonymous online questionnaire-based survey was conducted among Dutch emergency physicians and cardiologists between July 2015 and February 2016. The questionnaire was based on the American Heart Association CACP treatment algorithm.
Results: A total of 214 subjects were enrolled and completed the questionnaire. All responders considered cocaine use a risk factor for developing acute coronary syndrome (ACS), nevertheless 74.4 % of emergency physicians and 81.1 % of cardiologists do not always question chest pain patients about drug use. Of all responders, 73.6 % never perform toxicology screening. Most responders (60 %) observe patients with CACP according to the European Society of Cardiology ACS guideline, and 24.3 % give these patients ß-blockers.
Conclusion: The current practice for CACP patients in most emergency departments and coronary care units in the Netherlands is not in line with the AHA scientific statement. Emergency physicians and cardiologists should be advised to routinely question all chest pain patients on drug history and be aware that the risk stratifications scores are not validated for CACP. Despite the AHA scientific statement of 2008, many respondents utilize ß-blockers for CACP patients, which is supported by published evidence since the statement appeared.
Keywords: Chest pain; Cocaine; Observation.
© 2020 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Application of European Society of Cardiology guidelines for evaluating acute coronary syndrome risk in low-risk patients with cocaine-associated chest pain: Findings from the RISK study - An observational analysis.Toxicol Rep. 2024 Jun 18;13:101680. doi: 10.1016/j.toxrep.2024.05.010. eCollection 2024 Dec. Toxicol Rep. 2024. PMID: 39006369 Free PMC article.
-
The prognostic value of HEART score in patients with cocaine associated chest pain: An age-and-sex matched cohort study.Am J Emerg Med. 2021 Jul;45:303-308. doi: 10.1016/j.ajem.2020.08.074. Epub 2020 Aug 27. Am J Emerg Med. 2021. PMID: 33041125 Free PMC article.
-
Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain.Front Psychiatry. 2021 Jul 21;12:704276. doi: 10.3389/fpsyt.2021.704276. eCollection 2021. Front Psychiatry. 2021. PMID: 34366936 Free PMC article.
-
Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.Emerg Med J. 2018 Sep;35(9):559-563. doi: 10.1136/emermed-2017-207065. Epub 2018 Jun 19. Emerg Med J. 2018. PMID: 29921621 Free PMC article.
-
Rethinking cocaine-associated chest pain and acute coronary syndromes.Mayo Clin Proc. 2011 Dec;86(12):1198-207. doi: 10.4065/mcp.2011.0338. Mayo Clin Proc. 2011. PMID: 22134939 Free PMC article. Review.
Cited by
-
Modified HEART score to optimize risk stratification in cocaine-associated chest pain.Am J Emerg Med. 2021 Sep;47:307-308. doi: 10.1016/j.ajem.2021.01.023. Epub 2021 Jan 15. Am J Emerg Med. 2021. PMID: 33494961 Free PMC article. No abstract available.
-
Application of European Society of Cardiology guidelines for evaluating acute coronary syndrome risk in low-risk patients with cocaine-associated chest pain: Findings from the RISK study - An observational analysis.Toxicol Rep. 2024 Jun 18;13:101680. doi: 10.1016/j.toxrep.2024.05.010. eCollection 2024 Dec. Toxicol Rep. 2024. PMID: 39006369 Free PMC article.
-
Assessing the Potential of Untargeted SWATH Mass Spectrometry-Based Metabolomics to Differentiate Closely Related Exposures in Observational Studies.Metabolites. 2022 Oct 4;12(10):942. doi: 10.3390/metabo12100942. Metabolites. 2022. PMID: 36295843 Free PMC article.
-
Recreational drug use among young, hospitalized patients with acute coronary syndrome: A retrospective study.Toxicol Rep. 2022 Nov 8;9:1993-1999. doi: 10.1016/j.toxrep.2022.10.016. eCollection 2022. Toxicol Rep. 2022. PMID: 36518490 Free PMC article.
References
-
- instituut T. Nationale drug monitor jaarbericht 2016 2017 [Available from: https://www.trimbos.nl/actueel/nieuws/bericht/jaarbericht-2016-van-de-nationale-drug-monitor-verschenen.
-
- Amsterdam E.A., Wenger N.K., Brindis R.G. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2014;2014(64):139–228. - PubMed
-
- O’Gara P.T., Kushner F.G., Ascheim D.D. ACCF/AHA guideline for the management of ST-elevation myocardial infarction. JACC. 2013;61(4):78–140. 2013. - PubMed
-
- Collet J.P., Thiele H., Barbato E. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2020;2020(00):1–79. - PubMed
-
- Ibanez B., James S., Agewall S. ESC Guidelines for the management of Acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2017;2018(39):119–177. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources